Current Report Filing (8-k)
April 06 2021 - 8:31AM
Edgar (US Regulatory)
0001023024
false
0001023024
2021-04-06
2021-04-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): April 6, 2021
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-31812
|
58-2301143
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
210 Main Street West
Baudette, Minnesota
|
|
56623
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code: (218) 634-3500
(Former name or former
address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class:
|
|
Trading
Symbol(s):
|
|
Name
of each exchange on which registered:
|
Common Stock
|
|
ANIP
|
|
Nasdaq Stock Market
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2)
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD Disclosure.
On
April 6, 2021, ANI Pharmaceuticals, Inc. issued a press release announcing its acquisition of the new drug applications for OXISTAT®
Lotion, VEREGEN® Ointment, Pandel® Cream and the abbreviated new drug application for ApexiCon®
E Cream from Sandoz Inc., a global leader in generic pharmaceuticals. The press release announcing the acquisition is furnished as
Exhibit 99.1 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
ANI PHARMACEUTICALS, INC.
|
|
By:
|
/s/ Stephen P. Carey
|
|
|
Stephen P. Carey
|
|
|
Senior Vice President Finance, and Chief Financial Officer
|
Dated: April 6, 2021
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Apr 2024 to May 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From May 2023 to May 2024